More information about AVACTA GRP. ORD 10P

Our mission is to shape the future of medicine by developing safe and efficacious drugs based on our proprietary Affimer® platform and by providing powerful Affimer® reagents for research and diagnostics At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets. Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.